米非司酮对子宫肌瘤组织SULT1E1和雌激素受体α、β受体蛋白的影响

The Effect of Mifepristone on the SULT1E1 in Uterine Fibroid Tissue,ERα and ERβ Protein Levels

目的探讨米非司酮对子宫肌瘤组织雌激素硫酸转移酶(SULT1E1)、雌激素受体(ER)α和ERβ蛋白的影响。方法选择2013年10月至2015年4月重庆市大渡口区人民医院接诊的子宫肌瘤患者110例。按照随机数字表法分为观察组和对照组,各55例。对照组给予术前常规临床检查后口服安慰剂一片,连续服用90 d后进行手术治疗。观察组在术前常规临床检查的基础上联合米非司酮进行治疗,于患者月经第1天起口服米非司酮12.5 mg,连续服用90 d后进行手术。比较两组患者服药前后肿瘤体积水平的变化情况,SULT1E1含量,ERα、ERβ蛋白积分水平的变化情况及其治疗效果。结果观察组的总有效率为83.64%(46/55),高于对照组的45.45%(25/55),差异有统计学意义(P<0.05);服药后,观察组肿瘤体积显著低于对照组[(96.32±4.65)mm^3比(132.58±4.64)mm^3],差异有统计学意义(P<0.01);观察组SULT1E1、ERα、ERβ蛋白含量低于对照组[(28.24±3.47)%比(33.67±3.92)%,(0.32±0.05)%比(0.58±0.04)%,(0.09±0.01)%比(0.12±0.01)%],差异有统计学意义(P<0.01)。结论米非司酮对子宫肌瘤患者的治疗效果良好,减小肿瘤体积,降低SULT1E1和ERα、ERβ蛋白含量,可显著提高疗效,值得临床推广。

Objective To evaluate the effect of mifepristone on the uterine fibroid tissue sulfotransferases 1E1 （ SULT1E1 ）, estrogen receptor α（ERα） and ERβ protein levels. Methods Total of 110 patients with uterine fibroid tissue in People＇s Hospital of Chongqing Dadukou District from Oct. 2013 to Apr. 2015 were included. According to the random number table method they were divided into an observation group and a control group ,55 cases each. The control group given preoperative oral placebo after a routine clinical examination, taking 90 consecutive surgery treatment in the future. Observation group on the basis of preoperative routine clinical examination joint treated with mifepristone, the first day of menstruation in patients with oral mifepristone 12.5 mg,taking 90 consecutive surgery in the future. Changes in the two groups before and after treatment were compared with tumor volume level, SULT1 E1 content, ERa, ERR integration level changes and therapeutic effect of the two groups were compared. Results Total effective rate of the observation group was higher than the control group [ 83.64% （46/55） vs 45.45 % （25/55） ], the difference was statistically significant（ P 〈 0. 05 ） ;after treatment, tumor volume of the observation group was lower than the control group [ （96.32 ± 4. 65 ） mm3 vs （ 132.58 ± 4. 64） mm31, the difference was statistically significant （ P 〈 0. 01 ） ; SULT1E1, ERα, ERβ of the observation group were lower than the control group [ （ 28.25 ± 3.47）% vs （33.67 ±3.92）% ,（0.32 ±0.05）% vs （0.58 ±0.04）% ,（0.09 ±0.01）% vs （0. 12 ± 0.01）%],the differences were statistically significant（P 〈0.01）. Conclusion Mifepristone has good effect for uterine fibroid patient,which can reduce tumor size, lower SULT1E1 and ERα, ERβ level, with significantly improved efficacy, thus is worthy of promotion in clinical.